Quanterix Corp
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Expected move
Inputsspot 2.91exp Nov 20ATM strike 2.5ATM straddle 1.15IV 216%
−39.95%
vs ±31.9% implied · ×1.25
shaded = implied · ▲▼ = realized
Linked news
NewsQuanterix has 12 disclosed suppliers and 1 disclosed customer in SEC filings.
SentenceOur Spatial Biology instruments are manufactured by Columbia Tech, based in Westborough, Massachusetts.
QTRX 10-Kaccession 0001503274-26-000013
SentenceThe transaction is part of our plans to secure the use of Emission's highly controlled beads in our next generation platforms and expansion into a new multi-plex segment targeting third-party original equipment manufacturer customers.
QTRX 10-Kaccession 0001503274-26-000013
SentenceOur SR-X instrument is supplied by Paramit, based in Morgan Hill, California, and is shipped to our global customers by Paramit.
QTRX 10-Kaccession 0001503274-26-000013
SentenceThrough the acquisition of Akoya, the Company assumed a license and contingent payment obligation ("PKI License") from Akoya's 2018 purchase of the QPS division of PerkinElmer, Inc., subsequently known as Revvity, Inc.
QTRX 10-Kaccession 0001503274-26-000013
SentenceThrough the acquisition of Akoya, the Company assumed a license and contingent payment obligation ("PKI License") from Akoya's 2018 purchase of the QPS division of PerkinElmer, Inc., subsequently known as Revvity, Inc.
QTRX 10-Kaccession 0001503274-26-000013
SentenceIn November 2015, Akoya entered into an exclusive (equity) agreement with Stanford University ("Stanford"), pursuant to which Stanford granted Akoya an exclusive, sublicensable (subject to certain requirements), worldwide license under certain patent rights owned by Stanford relating to oligonucleotide-based biological sample labeling to make, use and sell products and services that are covered by such patent rights (the "Stanford Licensed Products") in all fields of use.
QTRX 10-Kaccession 0001503274-26-000013
SentenceOur HD-X instrument is supplied by STRATEC, based in Birkenfeld, Germany, and is manufactured and shipped from its Birkenfeld and Beringen, Switzerland facilities.
QTRX 10-Kaccession 0001503274-26-000013
Sentence10.11.1* Supply and Manufacturing Agreement, dated September 14, 2011, between the Registrant and STRATEC Biomedical AG S-1 11/9/2017 333-221475
QTRX 10-Kaccession 0001503274-26-000013
SentenceSimoa disks for our bead-based platforms are supplied through a single source supplier pursuant to a long-term supply agreement with STRATEC Consumables GmbH, a subsidiary of STRATEC.
QTRX 10-Kaccession 0001503274-26-000013
SentenceIn June 2007, as amended in April 2013, August 2017, and September 2020, we entered into a license agreement with Tufts, pursuant to which we obtained an exclusive, worldwide license to all patent rights to the Simoa bead-based technology owned by Tufts, as well as a non-exclusive license to related know-how.
QTRX 10-Kaccession 0001503274-26-000013
SentenceIn addition, we sell NfL antibodies and NfL ELISA kits produced by our Swedish subsidiary, UmanDiagnostics AB ("Uman"), directly and in conjunction with a distributor worldwide.
QTRX 10-Kaccession 0001503274-26-000013
SentenceIn June 2018, Akoya entered into an exclusive patent license agreement with the University of Washington (the "University"), pursuant to which the University granted Akoya an exclusive, sublicensable (subject to certain conditions), worldwide license in certain fields of use under certain patent rights owned by the University relating to technology for molecular profiling of cells and tissue specimens, to make, use and sell products that are covered by such patent rights, or the Washington Licensed Products.
QTRX 10-Kaccession 0001503274-26-000013
SentenceThis decrease was primarily due to a decrease of $18.8 million, or 37%, in the legacy Quanterix business due to the macro-economic conditions impacting demand for large projects from pharmaceutical customers and the completion of an agreement with Eli Lilly and Company which generated $4.5 million of revenue in 2024.
Quanterix Corp
2.89